Compare TSLX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | NVCR |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.0B |
| IPO Year | 2011 | 2015 |
| Metric | TSLX | NVCR |
|---|---|---|
| Price | $17.35 | $16.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $21.61 | ★ $28.08 |
| AVG Volume (30 Days) | 749.6K | ★ 1.7M |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | $1.20 | $6.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $16.04 | $9.82 |
| 52 Week High | $25.17 | $18.92 |
| Indicator | TSLX | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 56.90 |
| Support Level | $17.20 | $12.79 |
| Resistance Level | $18.48 | $18.59 |
| Average True Range (ATR) | 0.47 | 0.83 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 64.40 | 76.47 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.